REDUCING THE IMPACT OF CHRONIC KIDNEY DISEASE (CKD): OPPORTUNITIES FOR RANDOMIZED CLINICAL TRIALS

1. Discuss critical elements of the study design to optimize the conduct and impact of Phase III clinical trials in CKD.
2. Identify interventions and therapies for CKD that are currently in clinical trials or are ready to be evaluated in clinical trials.
3. Discuss mechanisms for pathways of cooperation among industry, academia, government, and patient advocacy groups for CKD trials.

For questions concerning program content, contact:
Dr. Michael Flessner, NIDDK, NIH
flessnermf@niddk.nih.gov

Dr. Yining Xie, NIDDK, NIH
xieyi@niddk.nih.gov